Regulation of hematopoietic stem cell self-renewal by NUP98-HOXA9

NUP98-HOXA9对造血干细胞自我更新的调控

基本信息

  • 批准号:
    8006300
  • 负责人:
  • 金额:
    $ 36.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-06-29 至 2014-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): One of the most elusive goals in hematologic research has been to understand how hematopoietic stem cells (HSC) self-renew, since this knowledge could be applied in protocols to expand clinically useful numbers of HSC for bone marrow transplantation and targeted gene therapy for hematologic disorders. A number of studies have suggested an essential role for homeodomain-containing proteins belonging to the Hox gene family in the regulation of adult HSC self-renewal. Experiments where the homeobox gene, Hoxb4, was overexpressed using a retroviral vector in HSC resulted in a 40-fold expansion in long-term repopulating HSC (LT-HSC) numbers in vitro. A similar stimulation of LT-HSC symmetric self-renewal in vitro was observed when Hoxb6 or Hoxa9 were overexpressed in LT-HSC. Loss of Mll, a mammalian trithorax homolog that functions to maintain Hox gene expression, results in the loss of adult LT-HSC in vivo, which further supports the hypothesis that Hox gene activity is essential for HSC self-renewal. Recent experiments where the acute myeloid leukemia oncoprotein NUP98-HOXA10 was expressed in murine hematopoietic progenitor cells using a retroviral vector showed an unprecedented 10,000-fold expansion of LT-HSC over a two-week in vitro culture period. In studies outlined in this proposal, we have observed a similar 10,000-fold in vitro expansion of adult LT-HSC using a related Hox fusion protein, NUP98-HOXA9. The major objective of this proposal will be to delineate the molecular mechanisms responsible for the dramatic enhancement of LT-HSC symmetric self-renewal mediated by NUP98- HOXA9 using genetic and biochemical approaches. In Aim 1, we will functionally test whether genes commonly up-regulated in LT-HSC by NUP98-HOXA9, Hoxb4, and Hoxa9 contribute to NUP98-HOXA9- mediated symmetric self-renewal. For Aim 2, we will characterize the extent to which Hoxa5 and Hoxb5 contribute to the potent HSC self-renewal phenotype stimulated by NUP98-HOXA9. Hoxa5 and Hoxb5 are the two most highly up-regulated Hox genes in LT-HSC expressing NUP98-HOXA9 so these paralogous genes may have a unique function in stimulation of LT-HSC expansion. Finally, in Aim 3 we will define the roles of the Hox co-factors, Pbx1 and Pbx3, in LT-HSC self-renewal mediated by Hoxb4 and NUP98- HOXA9 and identify NUP98-HOXA9-interacting proteins in LT-HSC using mass spectrometry. Our ability to expand LT-HSC 10,000-fold in vitro using NUP98-HOXA9 will allow, for the first time, conventional biochemistry to be done using a pure population of LT-HSC. This will facilitate the biochemical characterization of Hox protein complexes that are functioning in LT-HSC to regulate the self-renewal process. Collectively, these studies will provide new insights into the genes and pathways controlling adult LT-HSC symmetric self-renewal that is stimulated by Hox gene activity. PUBLIC HEALTH RELEVANCE: The ability to expand hematopoietic stem cells (HSC) in vitro to clinically useful numbers has tremendous application in the areas of bone marrow transplantation and gene therapy for hematologic disorders. In this proposal, we will explore the underlying molecular basis for the dramatic 10,000-fold ex vivo expansion of adult bone marrow HSC that is stimulated by the Hox fusion protein, NUP98-HOXA9.
描述(由申请人提供):血液学研究中最难以捉摸的目标之一是了解造血干细胞(HSC)如何自我更新,因为可以将这些知识应用于方案中,以扩大临床上有用的HSC数量的HSC,用于骨髓移植和靶向血液学疾病的基因治疗。许多研究表明,在成人HSC自我更新的调节中,属于HOX基因家族的含同源域蛋白的重要作用。 HSC中使用逆转录病毒载体过表达同源基因HOXB4的实验,导致长期重新流传HSC(LT-HSC)数量的40倍膨胀。当LT-HSC中过表达HOXB6或HOXA9时,观察到LT-HSC对称自我更新的类似刺激。 MLL的丧失是一种哺乳动物的Trithorax同源物,可维持HOX基因表达,导致体内成年LT-HSC的丧失,这进一步支持了HOX基因活性对于HSC自我更新至关重要的假设。最近的实验,急性髓细胞性白血病NUP98-HOXA10在使用逆转录病毒载体的鼠造血祖细胞中表达了肌肉造血祖细胞,显示了在两周的体外培养时期内LT-HSC的前所未有的10,000倍。在该提案中概述的研究中,我们使用相关的HOX融合蛋白NUP98-HOXA9观察到了成人LT-HSC的10,000倍体外扩张。该提案的主要目的是描述负责使用遗传和生化方法介导的LT-HSC对称自我更新LT-HSC对称自我更新的分子机制。在AIM 1中,我们将在功能上测试NUP98-HOXA9,HOXB4和HOXA9在LT-HSC中通常上调的基因是否有助于NUP98-HOXA9-介导的对称自我恢复。对于AIM 2,我们将表征HOXA5和HOXB5对NUP98-HOXA9刺激的有效HSC自我更新表型的贡献的程度。 HOXA5和HOXB5是表达NUP98-HOXA9的LT-HSC中两个最高上调的HOX基因,因此这些副基因可能在刺激LT-HSC膨胀方面具有独特的功能。最后,在AIM 3中,我们将定义HOXB4和NUP98-HOXA9介导的LT-HSC自我更新中HOX辅助因子PBX1和PBX3的作用,并识别LT-HSC在LT-HSC中使用质谱法中的NUP98-Hoxa9-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa-Hoxa9。我们使用NUP98-HOXA9在体外扩展LT-HSC 10,000倍的能力将首次使用LT-HSC的纯种群进行常规的生物化学。这将促进在LT-HSC中起作用以调节自我更新过程的HOX蛋白复合物的生化表征。总的来说,这些研究将提供有关由HOX基因活性刺激的成年LT-HSC对称自我更新的基因和途径的新见解。 公共卫生相关性:在体外扩展造血干细胞(HSC)到临床上有用的数字的能力在血液学疾病中具有巨大的应用。在此提案中,我们将探索由HOX融合蛋白NUP98-HOXA9刺激的成年骨髓HSC的10,000倍离体扩增的基本分子基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CHRISTOPHER KLUG其他文献

CHRISTOPHER KLUG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CHRISTOPHER KLUG', 18)}}的其他基金

Defining the role of Wnt11 and Wnt5a in regulating hematopoietic and skeletal stem cell self-renewal potential during homeostasis and stress
定义 Wnt11 和 Wnt5a 在稳态和应激过程中调节造血和骨骼干细胞自我更新潜力的作用
  • 批准号:
    10731650
  • 财政年份:
    2023
  • 资助金额:
    $ 36.63万
  • 项目类别:
Defining pathways promoting HSC self-renewal by mesenchymal stem/stromal cells
定义间充质干细胞/基质细胞促进 HSC 自我更新的途径
  • 批准号:
    9126155
  • 财政年份:
    2015
  • 资助金额:
    $ 36.63万
  • 项目类别:
Regulation of hematopoietic stem cell self-renewal by NUP98-HOXA9
NUP98-HOXA9对造血干细胞自我更新的调控
  • 批准号:
    8269740
  • 财政年份:
    2010
  • 资助金额:
    $ 36.63万
  • 项目类别:
Regulation of hematopoietic stem cell self-renewal by NUP98-HOXA9
NUP98-HOXA9对造血干细胞自我更新的调控
  • 批准号:
    8471160
  • 财政年份:
    2010
  • 资助金额:
    $ 36.63万
  • 项目类别:
Role of NF-kB in hematopoietic stem cells and leukemia-initiating cell formation
NF-kB 在造血干细胞和白血病起始细胞形成中的作用
  • 批准号:
    8022931
  • 财政年份:
    2010
  • 资助金额:
    $ 36.63万
  • 项目类别:
Role of NF-kB in hematopoietic stem cells and leukemia-initiating cell formation
NF-kB 在造血干细胞和白血病起始细胞形成中的作用
  • 批准号:
    8433499
  • 财政年份:
    2010
  • 资助金额:
    $ 36.63万
  • 项目类别:
Role of NF-kB in hematopoietic stem cells and leukemia-initiating cell formation
NF-kB 在造血干细胞和白血病起始细胞形成中的作用
  • 批准号:
    8607152
  • 财政年份:
    2010
  • 资助金额:
    $ 36.63万
  • 项目类别:
Role of NF-kB in hematopoietic stem cells and leukemia-initiating cell formation
NF-kB 在造血干细胞和白血病起始细胞形成中的作用
  • 批准号:
    8213544
  • 财政年份:
    2010
  • 资助金额:
    $ 36.63万
  • 项目类别:
Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma
早期检测胰腺导管腺癌的生物标志物发现
  • 批准号:
    7962113
  • 财政年份:
    2010
  • 资助金额:
    $ 36.63万
  • 项目类别:
Regulation of hematopoietic stem cell self-renewal by NUP98-HOXA9
NUP98-HOXA9对造血干细胞自我更新的调控
  • 批准号:
    8102969
  • 财政年份:
    2010
  • 资助金额:
    $ 36.63万
  • 项目类别:

相似国自然基金

成人型弥漫性胶质瘤患者语言功能可塑性研究
  • 批准号:
    82303926
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
MRI融合多组学特征量化高级别成人型弥漫性脑胶质瘤免疫微环境并预测术后复发风险的研究
  • 批准号:
    82302160
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
SMC4/FoxO3a介导的CD38+HLA-DR+CD8+T细胞增殖在成人斯蒂尔病MAS发病中的作用研究
  • 批准号:
    82302025
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
融合多源异构数据应用深度学习预测成人肺部感染病原体研究
  • 批准号:
    82302311
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Preclinical Validation of Personalized Molecular Assays for Measurable Residual Disease Monitoring in Pediatric AML
用于儿科 AML 可测量残留疾病监测的个性化分子检测的临床前验证
  • 批准号:
    10643568
  • 财政年份:
    2023
  • 资助金额:
    $ 36.63万
  • 项目类别:
Targeting Pediatric Cancer Vulnerabilities
针对儿童癌症的脆弱性
  • 批准号:
    10737704
  • 财政年份:
    2023
  • 资助金额:
    $ 36.63万
  • 项目类别:
Lineage-specific signaling and targeting of PI3K gamma in myeloid malignancies
髓系恶性肿瘤中 PI3K γ 的谱系特异性信号传导和靶向
  • 批准号:
    10595677
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
A Precision Medicine Tool for Optimal Personalized Treatment in Patients with Acute Myeloid Leukemia
用于急性髓系白血病患者最佳个性化治疗的精准医疗工具
  • 批准号:
    10547266
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
Diversifying Acute Leukemia Clinical Trial Enrollment Through Multilevel Intervention
通过多层次干预使急性白血病临床试验招募多样化
  • 批准号:
    10505579
  • 财政年份:
    2022
  • 资助金额:
    $ 36.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了